Research output per year
Research output per year
Personal profile
Campus career
医学科 助教 2017/04/01-2019/09/30
環境生体防御医学系 助教 2017/04/01-2019/09/30
医学系 助教 2019/10/01-
医学科 助教 2019/10/01-
医学部医学科 基幹教員
学部運営への参画状況・・・有-医学科医学教育推進専門委員会
担当授業科目に係る状況・・・主要授業科目担当
環境生体防御医学系 助教 2017/04/01-2019/09/30
医学系 助教 2019/10/01-
医学科 助教 2019/10/01-
医学部医学科 基幹教員
学部運営への参画状況・・・有-医学科医学教育推進専門委員会
担当授業科目に係る状況・・・主要授業科目担当
Fingerprint
Dive into the research topics where Shingo Imanishi is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
Research output
- 34 Article
-
A Case of EGFR‐mutant Squamous Cell Lung Cancer Treated With Necitumumab Combination Therapy
Inomata, M., Furukawa, D., Takata, N., Tokui, K., Okazawa, S., Imanishi, S. & Nomura, S., 2025/03, In: In Vivo. 39, 2, p. 1207-1210 4 p.Research output: Contribution to journal › Article › peer-review
Open Access -
Effectiveness of Chemoimmunotherapy in Small-cell Lung Cancer Patients With a Poor Performance Status or Higher Neutrophil/Lymphocyte Ratio
Inomata, M., Takata, N., Seto, Z., Murayama, N., Tokui, K., Okazawa, S., Imanishi, S., Miwa, T., Hayashi, R. & Matsui, S., 2025/01, In: In Vivo. 39, 1, p. 467-472 6 p.Research output: Contribution to journal › Article › peer-review
-
An observational study on the efficacy of targeted therapy for pulmonary sarcomatoid carcinoma
Tsuda, T., Ichikawa, T., Matsumoto, M., Mizusihima, I., Azechi, K., Takata, N., Murayama, N., Hayashi, K., Hirai, T., Seto, Z., Tokui, K., Masaki, Y., Taka, C., Okazawa, S., Kambara, K., Imanishi, S., Taniguchi, H., Miwa, T., Hayashi, R. & Matsui, S. & 1 others, , 2024/12, In: Discover Oncology. 15, 1, 382.Research output: Contribution to journal › Article › peer-review
Open Access -
Comparison of the efficacy of first-/second-generation EGFR-tyrosine kinase inhibitors and osimertinib for EGFR-mutant lung cancer with negative or low PD-L1 expression
Inomata, M., Minatoyama, S., Takata, N., Hayashi, K., Hirai, T., Seto, Z., Tokui, K., Taka, C., Okazawa, S., Kambara, K., Imanishi, S., Miwa, T., Hayashi, R., Matsui, S. & Tobe, K., 2024, In: Molecular and Clinical Oncology. 20, 6, 43.Research output: Contribution to journal › Article › peer-review
-
Immune Checkpoint Inhibitor Therapy for Patients With Non-small Cell Lung Cancer Ineligible for Platinum Doublet Chemotherapy
Inomata, M., Minatoyama, S., Takata, N., Hayashi, K., Hirai, T., Seto, Z., Tokui, K., Taka, C., Okazawa, S., Kambara, K., Imanishi, S., Miwa, T., Matsuyama, K., Hayashi, R., Matsui, S. & Tobe, K., 2024/03, In: Anticancer Research. 44, 3, p. 1241-1245 5 p.Research output: Contribution to journal › Article › peer-review
1 Scopus citations
Courses
-
第一内科
Tobe, K., Shinoda, K., Imanishi, S., Okazawa, S., Inomata, M., Fujisaka, S. & Honoki, H. 2024/04/01 → 2025/03/31
Course
-
呼吸器系
Tobe, K., Hayashi, R., Tsuchiya, T., Imanishi, S., Okazawa, S., Inomata, M., Saitoh, J.-I., Okabe, M., Kamisaki, Y. & Hirabayashi, K. 2024/04/01 → 2024/09/30
Course
-
-
第一内科
Tobe, K., Shinoda, K., Imanishi, S., Okazawa, S., Inomata, M., Fujisaka, S. & Honoki, H. 2023/04/01 → 2024/03/31
Course
-
呼吸器系
Tsuchiya, T., Imanishi, S., Okazawa, S., Kambara, K., Noguchi, A., Inomata, M., Saitoh, J.-I., Okabe, M., Kamisaki, Y. & Hirabayashi, K. 2023/04/01 → 2023/09/30
Course